drugset / Trial / NCT01654380

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

NCT01654380

Phase 1 Completed 22 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelOther

Summary

LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, what effect this investigational drug has on the body, and how much should be given. This study will also measure how much of the investigational drug gets into the blood stream and how long it takes the body to get rid of it. The study has 2 parts: Part A will be conducted in healthy participants. Part B will be conducted in participants with type 1 diabetes mellitus (T1DM). This study will take approximately 10-14 days spread over 6-20 weeks, not including screening. Screening will be performed within 30 days of the start of the study.

Timeline

Start
2012-07
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Peglispro Protein / enzyme biologic 5.1 unknown Intravenous
Subject Insulin Peglispro Protein / enzyme biologic 10.2 unknown Intravenous
Subject Insulin Peglispro Protein / enzyme biologic 15.3 unknown Intravenous
Subject Insulin Peglispro Protein / enzyme biologic 37 unknown Intravenous
Subject Insulin Peglispro Protein / enzyme biologic 74.1 unknown Intravenous